The first and only treatment
in its class (ARNI)2†

Act with
PrENTRESTO®

To help reduce the incidence of
HF hospitalization and CV death1

ENTRESTO® (sacubitril/valsartan) is indicated for the treatment of heart failure with reduced ejection fraction (HFrEF) in patients with NYHA Class II or III, to reduce the incidence of cardiovascular (CV) death and heart failure (HF) hospitalization.

ENTRESTO® should be administered in combination with other heart failure therapies, in place of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB).

For ENTRESTO® tools, relevant publications and guidelines

Go to Resource Library

† Comparative clinical significance has not been established. ‡ The primary endpoint was defined as the time-to-first-event. ¶ Please consult guidelines for complete recommendations.3 ACEi: angiotensin-converting-enzyme inhibitor; ARB: angiotensin receptor blocker; ARNI: angiotensin receptor-neprilysin inhibitor; CCS: Canadian Cardiovascular Society; CV: cardiovascular; HF: heart failure; HFrEF: heart failure with reduced ejection fraction; NYHA: New York Heart Association.